HEAT-PPCI: A clear and welcome win for heparin | Zendy

Ahmed ElGuindy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HEAT-PPCI: A clear and welcome win for heparin

Author(s) -

Ahmed ElGuindy

Publication year - 2014

Publication title -

global cardiology science and practice

Language(s) - English

Resource type - Journals

ISSN - 2305-7823

DOI - 10.5339/gcsp.2014.7

Subject(s) - bivalirudin , medicine , antithrombotic , conventional pci , percutaneous coronary intervention , heparin , cardiology , myocardial infarction

The use of bivalirudin during primary percutaneous coronary intervention (PPCI) is perceived to be associated with less bleeding compared to unfractionated heparin (UFH). However, evidence supporting this observation is confounded by the frequent co-administration of glycoprotein IIb/IIIa inhibitors in the UFH arm in the majority of previous large trials. The "How Effective Are Antithrombotic Therapies in Primary PCI (HEAT-PPCI)" trial was conducted to test the efficacy and safety of UFH vesrus bivalirudin in patients undergoing PPCI when GP IIb/IIIa inhibitors are used selectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research